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Renal osteodystrophy in diabetic patients. To assess the effects of
diabetes mellitus on renal osteodystrophy, we examined the database of
256 patients (45% on hemodialysis and 55% on peritoneal dialysis) who
were prospectively studied in three Toronto dialysis centers between
October of 1987 and 1989. All patients had serial documentation of their
clinical, laboratory and risk parameters of bone disease, and completed
a series of investigations that included the deferoxamine test, measure-
ment of intact 1-84 PTH levels, and an iliac crest bone biopsy.
Twenty-five percent of these patients were diabetic. When compared to
non-diabetic patients, they were on dialysis for a shorter duration (2.4
0.3 vs. 4.7 0.3 years; P < 0.0002), used calcium carbonate as the
only phosphate binder more frequently (40 vs. 25%; P < 0.007), and had
lower parathyroid hormone levels (12 1.4 vs. 24 2.3 pmollliter; P <
0.002). High-turnover bone disorders (that is, osteitis fibrosa and mixed
disorder) were distinctly uncommon (8 vs. 33%; P < 0.01 by Fisher's
exact test), while the mild (19 vs. 9%; P = NS) and the aplastic
disorders (with mean stainable bone surface aluminum of 6.5 0.7%)
(46 vs. 31%; P = NS) tended to be more common in diabetic patients.
The prevalence of aluminum bone disease was the same in both groups
(27%). Diabetic patients ingested a smaller cumulative dose of alumi-
num gels (3.7 0.6 vs. 9.3 1.1 kg; P < 0.005), yet had a higher rate
of aluminum accumulation on bone surfaces than non-diabetic patients
(1.5 0.19 vs. 0.96 0.10% per month on dialysis; P < 0.015).
Although the cumulative exposure to aluminum gels remained the major
risk factor for aluminum bone disease (P < 0.0001), a positive interac-
tion was noted for diabetic mellitus to increase this risk (P < 0.05).
Thus, diabetes mellitus appears to predispose dialysis patients to low
bone-turnover states. In addition, it appears to increase aluminum
accumulation on bone surfaces and predisposes to aluminum bone
disease. The clinical significance of the aplastic disorder remains to be
defined.
Since the time when hemodialysis was first introduced for the
treatment of end-stage renal disease (ESRD), many therapeutic
advances have taken place. The introduction of continuous
ambulatory peritoneal dialysis (CAPD) [1], and the improved
results in transplantation due to better surgical and medical
management and the use of cyclosporin A [2] have given
nephrologists greater flexibility in managing patients with
ESRD. Concurrently, the patient composition selected for renal
replacement treatment has changed significantly.
Over the past decade the incidence of diabetic patients
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entering the renal replacement treatment program has grown by
125% in Canada and by 450% in the USA. Thus, diabetic
patients with nephropathy have now emerged as the single
largest group on renal replacement therapy [3, 4].
Previous studies have shown that patients with insulin-
dependent diabetes mellitus and normal renal function have
reduced bone mass, low bone formation rates and low parathy-
roid hormone levels when compared to age-matched normal
subjects [5, 61. In hemodialysis patients, those with diabetes
mellitus have also been noted to have lower plasma parathyroid
hormone levels and bone formation rates [7, 8], as well as
diminished parathyroid gland responsiveness to an acute hy-
pocalcemic challenge [9] when compared to non-diabetic con-
trols. Thus, it has been suggested that the diabetic state may
predispose dialysis patients to low turnover bone lesions
through its associated "relative" hypoparathyroidism [7—9].
However, since aluminum intoxication is also known to sup-
press parathyroid function [101, the interpretation of the above
studies has been confounded by the possible co-existence of
aluminum intoxication in many of the patients [7—9]. Recently,
in a multivariant analysis based on a largely unselected group of
dialysis patients, we have shown that diabetes mellitus is indeed
a risk factor for low-turnover bone disorders independent of the
effect of cumulative aluminum exposure and dialysis modality
[11]. In the present study, we examined the potential modulat-
ing role of diabetes mellitus on uremic osteodystrophy.
Methods
The study design and organization of the Renal Osteodystro-
phy Study have been detailed previously [11—13]. It was a
prospective, cross sectional study of renal bone disease.
Study design and data collection
In the Renal Osteodystrophy Study, we documented all the
risk factors and events for bone disease in all study patients
from the time of their initiation on dialysis, and throughout a
two-year study period. Clinical parameters assessed included:
musculoskeletal findings of proximal myopathy (tested at the
time of bone biopsy), unexplained bone pain or pathological
fracture(s), and unexplained neurological findings of ataxia,
dyspraxia, seizure or dementia. Laboratory parameters as-
sessed included serum total protein, albumin, calcium, phos-
phorus, alkaline phosphatase, hemoglobin, MCV and alumi-
num. Risk factors assessed included: patient age, sex, dialysis
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modality and duration, phosphate binder types and doses since
initiation of dialysis, vitamin D treatment, and a history of:
diabetes mellitus, failed renal transplant, parathyroidectomy
and bilateral nephrectomy.
Special investigations
Parathyroid hormone (1-84 i-PTH). Plasma samples were
assayed using an immunoradiometric assay (IRMA; Nichols
Institute, California, USA) with specificity for intact PTH
which does not detect carboxyl-terminal fragments (normal
range for patients without renal failure: 1 to 5.5 pmol/liter or
10—55 pg/mI) [14]. All blood samples were collected prior to
heparinization in hemodialysis patients.
Deferoxamine (DFO) test. A standard DFO dose of 40 mg/kg
was injected i.v. in hemodialysis and i.p. in peritoneal dialysis
patients, and pre- and post-DFO (drawn 36 to 48 hours post-
DFO in hemodialysis and 18 to 24 hours post-DFO in peritoneal
dialysis patients), and serum aluminum levels were collected
using trace mineral tubes [15]. All aluminum-containing medi-
cations were discontinued 48 hours prior to pre-DFO aluminum
sample, and were restarted only after the post-DFO aluminum
level was sampled. All serum aluminum levels were measured
using graphite furnace atomic absorption spectrophotometry
with a normal reference range < 560 nM (100 nM = 2.7 pg/liter)
[15]. Delta aluminum was defined as the incremental rise of
serum aluminum level after DFO as compared to baseline (that
is, post-DFO minus pre-DFO aluminum level) [12, 16].
Bone biopsy. A standard technique previously reported was
used in our study [17]. Briefly, double-tetracycline labeling with
two short courses of two different tetracyclines (tetracycline
and demeclocycline), separated by an interval of 17 days, was
given to all study patients prior to bone biopsy, An iliac crest
bone biopsy was obtained four to 10 days after the last dose of
demeclocycline. All biopsies were fixed in 10% neutral phos-
phate-buffered formalin for 24 hours and then transferred to
70% ethanol. Undecalcified sections of trabecular bone were
stained by the Goldner method [17, 18], by aurin-tricarboxylic
acid for detection of aluminum [18], and by prussian blue for
iron staining.
Class jfication of renal bone lesions
The following histologic classification used in this study had
been detailed previously [18]: (i) aplastic lesion (bone formation
rate (BFR) < 108 jsm2/mm2/day; osteoid area (OA) < 15%; and
fibrosis < 0.5%); (ii) osteomalacia (BFR < 108 sm2/mm2/day;
OA 15%; and fibrosis < 0.5%); (iii) mild lesion (BFR  108
sm2/mm2/day; OA < 15%; and fibrosis < 0.5%); (iv) osteitis
fibrosa (OF) (BFR  108 m2/mm2/day; OA < 15%; and fibrosis
 5%); (v) mixed lesion (Mx) (BFR  108 m2/mm2/day; OA 
15%; and fibrosis  0.5%).
Four bone disorder groupings used in this study have been
previously defined [12]: (1) Aluminum bone disease (ABD) was
defined as all cases of aplastic lesion or osteomalacia with
SBSA  25%. In addition, mild and mixed lesions with SBSA
25% and "normal" BFR (108 <BFR < 250 sm2/mm2/day) were
also defined as "transitional" lesions related to aluminum
intoxication and were included as aluminum bone disease [19].
(2) Osteitis fibrosa and mixed lesions (OF/Mx) (with stainable
bone surface aluminum (SBSA) < 25%) were combined into a
single grouping of high-turnover bone disorders. (3) The mild
Table 1. Histologic and pathophysiologic classifications of renal





OF Mixed OM Aplastic Mild
(Stainable bone surface Al  25%)
Aluminum
bone disease + + + +
(Stainable bone surface Al <25%)
High-turnover
bone disorders + +
Mild disorder +
Aplastic disorder +
Abbreviations are: OF, osteitis fibrosa; OM, osteomalacia.
All cases of mixed and mild disorders with stainable bone surface
aluminum  25% and "normal" bone formation rates between 108 and
250 m2/mm2/day were defined as aluminum bone disease (see Methods
for details).
disorder was defined histologically as above, but in addition all
cases had SBSA < 25%. (4) All cases of the aplastic lesions with
SBSA < 25% were categorized as the aplastic (APL) disorder.
The term "disorder" is used in this clinico-pathophysiologic
classification to avoid any confusion with the above histologic
classification (Table 1), and does not necessarily imply a
"disease" state. Finally, any case that did not fit into the above
categories was classified as indeterminate.
Study patients
Four hundred and forty-five of all the "current" as well as
new patients entering the ESRD program in the study centers
between October 1, 1987 and June 30, 1988 were assessed
serially with a minimal follow-up of one year during the study.
All patients were managed using a standardized protocol, and
were dialyzed with solutions containing a calcium concentra-
tion of 6.5 or 7 mg/dl (1.625 or 1.75 mmol/liter). At the
termination of our study, 268 patients (60% of the total popu-
lation) underwent the above special investigations. Two hun-
dred forty-eight of these patients were randomly selected and
the other twenty were referred because of their clinical findings
of bone disease. Deferoxamine test and/or bone biopsy speci-
mens were lost in four of the 268 patients; in five other patients,
biopsy specimens were inadequate for a pathologic diagnosis.
To simplify the data analysis, three patients with bone disorders
other than the above were further excluded (two with an
indeterminate diagnosis and one with osteomalacia unrelated to
aluminum intoxication). Thus, 256 patients were examined in
this study.
All the study patients gave informed consent after a full
explanation of the details, procedures, and potential risks of the
study. The research protocol and consent form were approved
by the institutional review board of the University of Toronto.
Statistical methods
All data are expressed as means SEM, or percent. Univari-
ate comparisons were made for various demographic and risk
factors, and clinical and laboratory findings for diabetic and
non-diabetic patients. Statistical testing for hypothesis genera-
tion was only performed on these parameters using unpaired
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diabetic(N = 193) P-value
Age at biopsy years 58 1.6 56 1.1 NS
Sex M/F 1.7 1.5 NS
Peritoneal dialysis % 65 52 NS
Dialysis duration years 2.4 0.3 4.7 0.3 <0.0002
Cumulative Al(OH)3 kg 1.4 0.2 3.4 0.3 <0.0007
CaCO3 dose glday 2.2 0.1 1.9 1.3 NS
On CaCO3 only % 40 25 <0.007
Vitamin D analogue % 8 15 NS
Failed renal allograft % 3 19 NS
Parathyroidectomy % 0 6 NS
Bilateral nephrectomy % 0 3 NS
Values are expressed as mean SEM, ratio or percent
exact test if appropriate) for proportions [20, 21]. If the contin-
uous variables were skewed, the analysis was performed using
data transformed by natural logarithms. All P-values reported
are two-tailed. In a multivariant analysis, we have previously
shown that cumulative dose of aluminum gels ingested since
dialysis was a major risk factor for aluminum bone disease [11].
In this study, we examined the relationship between the cumu-
lative aluminum dose and diabetes mellitus on the probability of
aluminum bone disease using logistic regression analysis [22].
All tests were performed using the SAS computer program [23].
Results
Table 3. Clinical and laboratory findings by diabetic status
Diabetic
(N = 63)
Non-diabetic(N = 193) P-value
Proximal myopathy % 29 37 NS
Unexplained bone pain 14 28 NS
%
Pathologic fracture(s) % 3 8 NS
[Ca] mmol/liter 2.35 0.03 2.44 0.02 NS
[P04] mmol/liter 1.82 0.06 1.94 0.05 NS
ALP U/liter 91 6.1 108 6.8 NS
1-84 PTH pmol/liter 11.5 1.4 24.0 2.3 <0.002
s-[Al] nmol/liter 1450 190 1540 120 NS
pre-DFO
Delta [Al] 2210 320 2870 210 NS
post-DFO nmol/liter
Values are expressed as mean SEM, or percent
Laboratory reference range: Plasma calcium ([Ca]) = 2.2—2.6 mmol/
liter; plasma phosphate ([P04]) = 0.7—1.3 mmollliter; alkaline phos-
phatase (ALP) <80 U/liter; intact 1-84 parathyroid hormone (1-84 PTH)






Forty-five percent of the study patients were on hemodialy-
sis, another 45% were on continuous ambulatory peritoneal
dialysis (CAPD), and 10% were on intermittent peritoneal
dialysis (IPD). Their demographics and risk factors for bone
disease by diabetic status are shown in Table 2. There were no
significant differences between the insulin-dependent and non-
insulin dependent diabetic patients with respect to their risk
factors, and clinical and laboratory parameters except for their
age (53 2.1 vs. 64 1.8, P < 0.0001). Thus, they were
combined into a single group. Overall, 25% of the patients were
diabetic. They were on dialysis for a shorter duration, had a
lower cumulative exposure to aluminum gels, and used calcium
carbonate as the only phosphate binder more frequently than
the non-diabetic patients. Table 3 shows the clinical and labo-
ratory findings of the diabetic and non-diabetic patients. There
were no significant differences except for lower parathyroid
hormone levels in the diabetic patients.
Bone disorders in the diabetic patients
Overall, 61% (157 of 256) of our patients were found to have
a low-turnover bone disorder on biopsy. Within this group, 44%
(69 of 157) had aluminum bone disease, and the remainder, the
aplastic (or "adynamic") disorder. High-turnover bone disor-
ders (that is osteitis fibrosa and the mixed disorder) were
distinctly uncommon while the mild and the aplastic disorders
tended to be more common in diabetic as compared to non-
diabetic patients (Fig. 1). The prevalence of aluminum bone
disease was the same in both groups. The mean (± SEM)
stainable bone surface aluminum in patients with the aplastic
disorder was not different from that in patients with the mild
Fig. 1. Prevalence of bone disorders in patients with (gray bar) and
without diabetes mellitus (white bar). High-turnover bone disorders
[that is, osteitis fibrosa and mixed disorder (OF/Mx)] were distinctly
uncommon (8 vs. 33%; P < 0.01 by Fisher's exact test), while the mild
(19 vs. 9%; P = NS) and the aplastic (APL) disorders (with mean SEM
stainable bone surface aluminum of 6.5 0.7%) (46 vs. 31%; P = NS)
tended to be more common in diabetic patients. The prevalence of
aluminum bone disease (ABD) was the same in both groups (27%). All
P-values reported are two-tailed and Bonferroni-adjusted for multiple
comparisons.
disorder (6.5 0.7 vs. 6.3 1.0%), and yet their bone
formation rates were significantly depressed. Selected bone
morphometric parameters for each specific bone disorders in
both diabetic and non-diabetic patients are shown in Table 4.
There were no differences in these parameters except in pa-
tients with aluminum bone disease where diabetic patients had
lower bone formation rates than non-diabetic patients despite
similar degrees of stainable bone surface aluminum.
Diabetes mellitus as a risk factor for aluminum bone disease
We compared the aluminum exposure and burden in both
diabetic and non-diabetic patients with aluminum bone disease
(Table 5). One non-diabetic patient who presented with alumi-
num intoxication within one month of initiating dialysis was
excluded from this analysis. In general, diabetic patients with
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Diabetic
(N = 63)
Non-diabetic(N = 193) P-value
Aluminum bone disease
BFR 4un2/rn,n2/day 35 12 98 17 0.04
SBSA % 42 3.5 48 2.2 NS
Fibrosis % 0.061 0.033 0.23 0.081 NS
OF/Mx disordera
BFR sm2/mm2/day 520 140 730 55 NS
SBSA % 19 10 14 1.9 NS
Fibrosis % 1.3 0.47 2.4 0.33 NS
Mild disorder
BFR sm2fmm2/day 220 80 270 40 NS
SBSA% 4.9 1.9 7.3 1.5 NS
Fibrosis % 0.17 0.031 0.18 0.031 NS
Aplastic disorder
BFR p.m2/mm2/day 25 5.2 27 3.8 NS
SBSA % 4.7 1.1 7.9 0.94 NS




(N = 51) P-value
Daily dose of 3.4 0.38 3.4 0.17 NS
aluminum gels
giday
Dialysis duration 38 6.0 91 10 <0.005
months
Cumulative dose of 2.9 0.54 6.9 0.82 <0.0002
aluminum gel
since dialysis kg
Delta Al] post-DFO 5000 760 5200 450 NS
nmol/liter
Stainable bone 42 3.5 48 2.2 NS
surface aluminum
(SBSA) %
Accumulation rate 1.5 0.19 0.96 0.10 <0,016
of SBSA
%/month
aluminum bone disease ingested the same daily dose of alumi-
num gels as non-diabetic patients with aluminum bone disease.
However, they were on dialysis for a shorter duration; thus,
their cumulative exposure to aluminum gels was significantly
less than that in non-diabetic patients. Nevertheless, the alumi-
num burden as assessed by delta aluminum post-deferoxamine
infusion and by the percentage of stainable surface aluminum
on bone biopsy was not different between the two groups. In
addition, the average rate of aluminum accumulation on bone
surfaces in diabetic patients was 50% higher than non-diabetic
patients. Logistic regression analysis showed that the cumula-
tive dose of aluminum gels ingested since dialysis was the major
risk factor for aluminum bone disease (P < 0.000 1), but diabetes
Fig. 2. Probability of aluminum bone disease [P(ABD)J in diabetic and
non-diabetic patients adjusted for the cumulative exposure of alumi-
num gels (ALUDOSE) ingested since dialysis (data expressed as
predictive value and 95% confidence intervals). The risk of aluminum
bone disease for diabetic patients was significantly higher, and doubled
that of non-diabetic patients once a threshold of 3 kg of aluminum gels
was ingested. In absolute terms, for example, there is a 50% probability
for a diabetic patient who ingested 3 kg of aluminum gels to develop
aluminum bone disease as compared to a 23% risk in a non-diabetic
patient. Conversely, for a non-diabetic patient, ingestion of 8 kg of
aluminum gels would be required to develop the same risk as the above
diabetic patient.
mellitus also interacted positively to increase this risk (P <
0.05). Figure 2 shows the probability of aluminum bone disease
by diabetic status adjusted for the cumulative exposure of
aluminum gels ingested. When the cumulative dose of alumi-
num gels was 3 kg or more, the probability for aluminum bone
disease doubled in diabetic patients as compared to non-
diabetic patients.
Discussion
We found that low-turnover bone disorders were the most
common forms of osteodystrophy, occurring in 61% of our
patients [11—13]. Within this group of disorders, aluminum bone
disease accounted for 44%, and the aplastic disorder, the
remainder. In contrast, the finding of the aplastic disorder as
defined in our study with minimal or no stainable bone surface
aluminum was distinctively uncommon in previous studies of
uremic osteodystrophy [24—281. Thus, the emergence of this
disorder as the single most common finding in our patients was
most unexpected. In addition, we found that diabetes mellitus
was an independent risk factor for both aluminum bone disease
and the aplastic bone disorder [11].
In this study, we found that diabetic patients ingested a
significantly less cumulative dose of aluminum gels than non-
diabetic patients. Nevertheless, the prevalence of aluminum
bone disease was the same in both groups, raising the possibil-
ity that diabetic patients might be more prone to aluminum
intoxication. Indeed, the risk of aluminum bone disease for
diabetic patients was significantly higher, and doubled that of
non-diabetic patients once a threshold of 3 kg of aluminum gels
was ingested (Fig. 2). In absolute terms, for example, there is a
50% probability for a diabetic patient who ingested 3 kg of
aluminum gels (that is, over 2.5 years assuming a daily dose of
3.4 g) to develop aluminum bone disease as compared to a 23%
Table 4. Histomorphometric parameters in diabetic (DM) and non-
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Values are expressed as mean SEM, or percent
Reference range: Bone formation rate (BFR) = 108—580 sm2/mm2/
day; stainable bone surface aluminum (SBSA) < 1%; fibrosis in bone
biopsy < 0.1%.
a Osteitis fibrosa/mixed disorder.
Table 5. Aluminum exposure and accumulation in diabetic (DM) and
non-diabetic (non-DM) patients with aluminum bone disease (ABD)
Values are expressed as mean SEM, or percent
a One patient who presented with ABD within one month of dialysis
was excluded.
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risk in a non-diabetic patient. Conversely, a non-diabetic pa-
tient would have to ingest 8 kg of aluminum gels to develop the
same risk as the above diabetic patient.
We also examined the aluminum burden in our patients by
delta aluminum post-DFO infusion and by the percentage of
stainable surface aluminum on bone biopsy and found that they
were not different between the two groups. However, the rate
of accumulation of aluminum on bone surfaces in diabetic
patients was 50% higher than in non-diabetic patients. These
findings suggest the possibility that in diabetic patients gastro-
intestinal absorption of aluminum may be enhanced. In addi-
tion, the low-turnover state such as the aplastic disorder in
diabetic patients may also enhance aluminum accumulation in
the bone as suggested previously [291. Finally, in patients with
aluminum bone disease, diabetic patients had a more depressed
bone formation rate than non-diabetic patients, suggesting that
the modulating effect on bone turnover by aluminum intoxica-
tion and diabetes mellitus may be additive.
Although the pathogenesis of the aplastic disorder defined in
this study remains unclear [30, 31], we propose that it is not
related to aluminum intoxication. Despite its histologic similar-
ity to the aplastic lesion seen in aluminum intoxication, there
was no evidence of significant aluminum overload in our
patients with this disorder as assessed by the cumulative dose
of aluminum gels ingested since dialysis, the deferoxamine test
results, and the stainable surface aluminum on bone biopsy
[11]. Comparing with the mild disorder, patients with the
aplastic disorder had the same degree of stainable bone surface
aluminum, and yet their bone formation rates were depressed
(Table 4). Thus, aluminum intoxication is unlikely to play an
important role in the low-turnover state of this disorder. Re-
cently, a bovine parathyroid cell culture study suggests that
glucose and insulin may be independent modulating factors for
parathyroid function. Hyperglycemia and insulin deficiency
both inhibit parathyroid hormone release, and appear to inter-
act synergistically [32]. Furthermore, insulin treatment has
been shown to normalize the low parathyroid hormone levels
and bone formation rates in diabetic rats [33]. Given all these
findings, we believe that the diabetic state is an important factor
that may reduce bone turnover in dialysis patients through
modulation of parathyroid function [11]. Other potential factors
which have been implicated to predispose to a bone low-
turnover state include vitamin D treatment, parathyroidectomy,
corticosteroid therapy and immobilization [30]. However, they
did not appear to be important in our study. The clinical
significance of the aplastic disorder remains unclear at the
present time, since the follow-up of patients with this disorder
is relatively short.
In conclusion, diabetes mellitus appears to be an important
risk factor for both aluminum bone disease and the aplastic
bone disorder possibly through modulation of parathyroid func-
tion. Chronic aluminum exposure is the most important factor
for the development of aluminum bone disease, and diabetes
mellitus enhances this risk significantly, possibly by increasing
gastrointestinal absorption and bone surface accumulation of
aluminum. Thus, oral ingestion of aluminum-containing medi-
cations (that is aluminum gels and sulcrafate) in diabetic pa-
tients should be strictly eliminated if possible. The aplastic
disorder, seen in one-third of our patients, appears to be a novel
finding. Further studies are needed to define the clinical signif-
icance of this disorder in diabetic patients.
Reprint requests to York Pei, M.D., 13 EN-228, Toronto Hospital
(Toronto General Site), 200 Elizabeth Street, Toronto, Ontario, Can-
ada, M5G 2C4.
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